Short-term impact of modified blood-lipid reports on physicians' lipid lowering drug prescribing behavior and knowledge improvement on dyslipidemia / 中华心血管病杂志

<p><b>OBJECTIVE</b>To compare the physicians' lipid lowering drug prescribing behavior and knowledge on dyslipidemia before and at 8 months after new-issued blood-lipid reports in our hospital.</p><p><b>METHOD</b>Blood-lipid reports in our hospital is newly modified in that the classification of dyslipidemia and lipid-lowering guideline and target lipid level are listed on the back of lipid report besides the normal lipid value listed immediately after the measured lipid levels. Physicians' lipid lowering drug prescribing behavior and knowledge on dyslipidemia before and at 8 months after new-issued blood-lipid reports were examined in 143 doctors from various departments before and at 8 months after new-issued lipid reports.</p><p><b>RESULTS</b>At 8 months after the new issued lipid reports, doctors' cognition rate about the guideline was significantly increased [83.9% (120/143) vs. 67.1% (96/143), P < 0.001] and the guideline was considered more helpful on daily practice [75.3% (58/77) vs. 55.8% (43/77), P = 0.005] compared to baseline. However, the prescription rate of dyslipidemia therapy did not change significantly (69.2% vs. 63.2%, P = 0.117) at 8 months after the new issued lipid reports.</p><p><b>CONCLUSIONS</b>The modification of the blood-lipid reports improved doctors' knowledge on dyslipidemia and on the "Chinese guidelines on prevention and treatment of dyslipidemia in adults". However, the lipid lowering drug prescribing behavior remained unchanged at 8 months after the modification of the lipid reports. Further investigation is warranted to see if the lipid lowering drug prescribing behavior could be changed in the long-term.</p>

Average-12.9 chromosome imbalances coupling with 15 differential expression genes possibly involved in the carcinogenesis, progression and metastasis of supraglottic laryngeal squamous cell cancer / 中华医学遗传学杂志

<p><b>OBJECTIVE</b>With the objective of discovering novel putative chromosomal regions and special genes involved in the carcinogenesis, progression and metastasis of laryngeal squamous cell cancer (LSCC).</p><p><b>METHODS</b>DNA copy profile of LSCC were obtained and analyzed by comparative genomic hybridization (CGH) and a computerized digital image analysis system. cDNA microarray of LSCC was performed and the profile was analyzed by Hierarchical clustering.</p><p><b>RESULTS</b>CGH analysis showed average-12.9 gains and losses of chromosomes in LSCC. Relatively high frequencies of gains were found at 3q15-21 (14/18), 5p12-13 (11/18), 8q22-24 (6/18), 11q12-13 (8/18), 15q21-23 (7/18) and 18p11 (8/18), while those of losses at 1p13-21 (8/18), 3p21-23 (14/18), 5q21-22 (14/18), 9p12-pter (11/18) and 13q21-31 (8/18). Hierarchical clustering analysis showed that the differentially expressed genes were segregated into three groups. Three genes differentially expressed in process I (normal tissue to cancer) and process II (cancer to lymph node metastasis), and the Cy5/Cy3 ratios of twelve genes were either higher than 5.0 or lower than 0.2 in process I or process II. The fifteen special genes were first reported possibly to be the relationships with LSCC. In particular, 4 genes of them, which were cytochrome C oxidase Va, PPBP, EPHX2 and PON1, were first reported to correlate with tumorigenesis. SH3GL2, which was one of the 15 special genes, was located at one of the special chromosome regions, 9p12-pter.</p><p><b>CONCLUSION</b>The important genes and special chromosomal aberrances might provide us a clue for further investigation of carcinogenesis, progression and metastasis in LSCC.</p>

Study on STK15 gene abnormality and centrosomal amplification in laryngeal carcinoma / 中华医学遗传学杂志

<p><b>OBJECTIVE</b>To investigate STK15 gene abnormality and centrosomal amplification in laryngeal carcinoma.</p><p><b>METHODS</b>STK15 gene mRNA expressional level was tested in 62 cases of laryngeal squamous cell carcinoma and laryngeal squamous cell carcinoma cell line Hep-2 by reverse transcription-polymerase chain reaction(RT-PCR); the mutation of STK15 gene exon 6 and exon 7 in the same tissues and cells was detected by PCR-single strand conformation polymorphism. Immunofluorescent antibodies were used to test centrosomal amplification in Hep-2 cell line as an example.</p><p><b>RESULTS</b>STK15 gene overexpressed in 39 cases of laryngeal carcinoma (63%) and Hep-2 cell line. No mutation was found in exon 6 and exon 7 of STK15 gene in the above tissues and cells. Centrosomal amplification was apparent in Hep-2 cell line. The number of centrosome in a single cell changed from 1 to 7, and Hep-2 cells with amplified centrosomes (more than 2 in one cell) were 11%-23%.</p><p><b>CONCLUSION</b>STK15 gene overexpression and centrosomal amplification were first found in human laryngeal squamous cell carcinoma, which indicated that STK15 gene overexpression leading to centrosomal amplification might occur in the early stage of human laryngeal carcinogenesis and be one of the key mechanisms for the occurrence of laryngeal carcinoma.</p>